Fig 1.
Number vaccination and breakthrough infection density by week by rurality, January 1, 2021—December 20, 2021.
aBars represent number vaccinated and lines represent breakthrough infection rates.
Table 1.
Baseline characteristics of all patients in N3C receiving 2 doses of mRNA vaccine between January 1, 2021, and September 21, 2021.
Fig 2.
Kaplan Meier cumulative incidence curves for SARS-CoV-2 breakthrough infection following two mRNA vaccinations in adults, January 1, 2021 –December 20, 2021.
Fig 3.
Univariable and multivariable Cox-proportional hazard ratios for SARS-CoV-2 breakthrough infection following two mRNA vaccinations by community factors, January 1, 2021 –December 20, 2021.
A. Univariable Hazard Ratios for Key Factors Evaluated Independently. B. Multivariable* Hazard Ratios for Key Factors Evaluated Independently. *Models adjusted for age, gender, race/ethnicity, comorbid conditions, prior SARS-CoV-2 infection, vaccine manufacturer, period of vaccination (relative to Delta dominance), and US Census region. Full model specifications available in S2 and S3 Tables in S1 File.
Fig 4.
Multivariable Cox-proportional hazard ratios for SARS-CoV-2 breakthrough infection following two mRNA vaccinations in adults by combined key factors, January 1, 2021 –December 20, 2021.
Fig 5.
Differences in 30-day severity* based on vaccination status in persons infected with SARS-CoV-2, January 1, 2021 –December 20, 2021.
*Severity categories following SARS-CoV-2 infection classified as outpatient-only visit (no hospitalization within 30 days of diagnosis), COVID-associated hospitalization (within 30 days of diagnosis), COVID-19-associated adverse event (mechanical ventilation, ECMO, or death or transfer to hospice within 30 days of diagnosis).